Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|January 11, 2018

Pittcon 2018 Introduces 23 New Short Courses for Lab Professionals

The 2018 Short Course program at Pittcon, taking place Feb. 24–Mar. 1, will feature 23 new short courses geared towards laboratory professionals.

On Jan. 9, 2018, the Pittcon Short Course Committee announced the 2018 Short Course program being held Feb. 24–Mar. 1, 2018. The program has added 23 new courses for laboratory professionals.

Program offerings include more than 100 half-day to two-day courses at beginner and intermediate levels. Courses are taught by industry experts and cover a range of analytical topics including pharmaceutical, environmental, life science, and more. Additionally, comprehensive application and general lab function courses are available, and include lab management, data management, lab safety, and technical writing.

Topics covered by the 23 new courses added to this year’s program include sample preparation, advanced techniques in high-performance liquid chromatography, laboratory information management systems, scientific writing, and liquid handling. New course titles include:

  • New Technology Commercialization

  • How to be Successful in Scientific Publishing

  • Volume Verification, Good Liquid Handling, and Automated Sample Prep and Detection

  • Counter current Chromatography and Centrifugal Partition Chromatography.

Pittcon 2018 will be held Feb. 26 –Mar. 1 in Orlando, FL, at the Orange County Convention Center.

Source: Pittcon


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.